» Articles » PMID: 23349832

MicroRNA-22 (miR-22) Overexpression is Neuroprotective Via General Anti-apoptotic Effects and May Also Target Specific Huntington's Disease-related Mechanisms

Overview
Journal PLoS One
Date 2013 Jan 26
PMID 23349832
Citations 94
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Whereas many causes and mechanisms of neurodegenerative diseases have been identified, very few therapeutic strategies have emerged in parallel. One possible explanation is that successful treatment strategy may require simultaneous targeting of more than one molecule of pathway. A new therapeutic approach to have emerged recently is the engagement of microRNAs (miRNAs), which affords the opportunity to target multiple cellular pathways simultaneously using a single sequence.

Methodology/principal Findings: We identified miR-22 as a potentially neuroprotective miRNA based on its predicted regulation of several targets implicated in Huntington's disease (histone deacetylase 4 (HDAC4), REST corepresor 1 (Rcor1) and regulator of G-protein signaling 2 (Rgs2)) and its diminished expression in Huntington's and Alzheimer's disease brains. We then tested the hypothesis that increasing cellular levels of miRNA-22 would achieve neuroprotection in in vitro models of neurodegeneration. As predicted, overexpression of miR-22 inhibited neurodegeneration in primary striatal and cortical cultures exposed to a mutated human huntingtin fragment (Htt171-82Q). Overexpression of miR-22 also decreased neurodegeneration in primary neuronal cultures exposed to 3-nitropropionic acid (3-NP), a mitochondrial complex II/III inhibitor. In addition, miR-22 improved neuronal viability in an in vitro model of brain aging. The mechanisms underlying the effects of miR-22 included a reduction in caspase activation, consistent with miR-22's targeting the pro-apoptotic activities of mitogen-activated protein kinase 14/p38 (MAPK14/p38) and tumor protein p53-inducible nuclear protein 1 (Tp53inp1). Moreover, HD-specific effects comprised not only targeting HDAC4, Rcor1 and Rgs2 mRNAs, but also decreasing focal accumulation of mutant Htt-positive foci, which occurred via an unknown mechanism.

Conclusions: These data show that miR-22 has multipartite anti-neurodegenerative activities including the inhibition of apoptosis and the targeting of mRNAs implicated in the etiology of HD. These results motivate additional studies to evaluate the feasibility and therapeutic efficacy of manipulating miR-22 in vivo.

Citing Articles

Palmitoylation-related gene ZDHHC22 as a potential diagnostic and immunomodulatory target in Alzheimer's disease: insights from machine learning analyses and WGCNA.

Mao S, Zhao X, Wang L, Man Y, Li K Eur J Med Res. 2025; 30(1):46.

PMID: 39844282 PMC: 11752772. DOI: 10.1186/s40001-025-02277-0.


Site-blocking antisense oligonucleotides as a mechanism to fine-tune MeCP2 expression.

Vanderplow A, Dodis G, Rhee Y, Cikowski J, Gonzalez S, Smith M RNA. 2024; 30(12):1554-1571.

PMID: 39379106 PMC: 11571808. DOI: 10.1261/rna.080220.124.


Therapeutic effects of tetrahedral framework nucleic acids and tFNAs-miR22 on retinal ischemia/reperfusion injury.

Xu X, Fu Y, Luo D, Zhang L, Huang X, Chen Y Cell Prolif. 2024; 57(11):e13695.

PMID: 39086110 PMC: 11533083. DOI: 10.1111/cpr.13695.


Small extracellular vesicles derived from microRNA-22-3p-overexpressing mesenchymal stem cells protect retinal ganglion cells by regulating MAPK pathway.

Yu B, Wang K, Hao H, Liu Y, Yue Y, Li X Commun Biol. 2024; 7(1):807.

PMID: 38961177 PMC: 11222527. DOI: 10.1038/s42003-024-06511-z.


Neuroinflammation and the role of epigenetic-based therapies for Huntington's disease management: the new paradigm.

Temgire P, Arthur R, Kumar P Inflammopharmacology. 2024; 32(3):1791-1804.

PMID: 38653938 DOI: 10.1007/s10787-024-01477-0.


References
1.
Hockly E, Richon V, Woodman B, Smith D, Zhou X, Rosa E . Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A. 2003; 100(4):2041-6. PMC: 149955. DOI: 10.1073/pnas.0437870100. View

2.
Packer A, Xing Y, Harper S, Jones L, Davidson B . The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease. J Neurosci. 2009; 28(53):14341-6. PMC: 3124002. DOI: 10.1523/JNEUROSCI.2390-08.2008. View

3.
Steffan J, Bodai L, PALLOS J, Poelman M, McCampbell A, Apostol B . Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature. 2001; 413(6857):739-43. DOI: 10.1038/35099568. View

4.
Williams A, Valdez G, Moresi V, Qi X, McAnally J, Elliott J . MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science. 2009; 326(5959):1549-54. PMC: 2796560. DOI: 10.1126/science.1181046. View

5.
Runne H, Regulier E, Kuhn A, Zala D, Gokce O, Perrin V . Dysregulation of gene expression in primary neuron models of Huntington's disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry. J Neurosci. 2008; 28(39):9723-31. PMC: 6671220. DOI: 10.1523/JNEUROSCI.3044-08.2008. View